Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
Become a Member | Sign in
Home>News>This Article

Enzo Biochem Launches Test for Measuring Risk of Colorectal Cancer

Published: Thursday, April 12, 2012
Last Updated: Thursday, April 12, 2012
Bookmark and Share
Company developing pipeline of new platforms and assays for molecular diagnostic use.

Enzo Biochem Inc. announced the launch of the ColonSentry™ test for assessing a patient’s risk of having colorectal cancer, the first in a pipeline of new molecular diagnostic products the Company plans for the medical community.
“As a pioneer in the use of genomic and genetic information as a catalyst for diagnostic products for delivering better healthcare, the availability of ColonSentry™, which only recently received New York State Department of Health approval, marks another important chapter in the transformation of our Company,” said Barry Weiner, Enzo President.  
“We also have, pending for New York State approval, our first assay based test on our new proprietary low cost and highly sensitive AmpiProbe™ nucleic acid amplification and detection technology platform.  Our AmpiProbe™ HCV RNA Quantification assay has been tested over hundreds of clinical samples and found to be reliable, accurate and precise. In addition, our assay was found, as compared to similar diagnostics products, to achieve enhanced sensitivity that can allow for a more convenient and efficient workflow which may utilize significantly less starting material and consumables.  This product is the first of several assays now under development based on the AmpiProbe™ next generation molecular diagnostics platform that are expected to be marketed both nationally and internationally.  
“These developments underscore the opportunities available to our Company through the combination of a world class clinical lab and ground breaking life science capability.  Today’s announcement of the effective roll out of ColonSentry™ is a significant achievement pointing towards a highly promising era for Enzo.”
ColonSentry™ is a first of its kind blood-based risk stratification test for colorectal cancer.  It utilizes RNA to measure the level of expression of seven specific genes. ColonSentry™ requires only a small sample of blood that can be easily collected during a routine physical exam. It is being made available as a tool to help assess a patients’ risk for colorectal cancer, and thus drive greater compliance for use of colonoscopies, which has been very low, and contribute to earlier detection of colorectal cancer.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Signaling Pathway Could Be Key to Improved Osteoporosis Treatment
Inhibition of SIK2 enzyme both stimulates bone formation and reduces bone breakdown in animal model.
Cocoa Compound Linked to Some Cardiovascular Biomarker Improvements
The study highlights the urgent need for large, long-term RCTs that improve understanding of how the short-term benefits of cocoa flavanol intake on cardiometabolic biomarkers may be translated into clinical outcomes.
New Pathway for COPD Biomarker Development
A study from Philip Morris International has highlighted multi-lipid profiling as a potential new pathway for COPD biomarker development.
Anti-Cancer Drug Uses Tumour mRNA to Identify Responders
Phase I study of novel anti-cancer drug uses tumour mRNA expression to identify patients who will respond to the drug.
Genetic Signature Linked to Cancer Prognosis Identified
The results of the analysis of 8,161 tissue samples could in the future help clinicians decide how best to treat a patient as well as aid the development of new targeted treatments.
NIH Commits $6.7 M to Advance DNA, RNA Sequencing Technology
"Can you believe they make DNA sequencers the size of staplers?" asked Meni Wanunu, Ph.D. "Ideas that were crazy twenty years ago are now happening!"
Curcumin Shows Promise as Cancer Treatment
When delivered at the correct circadian phase, curcumin demonstrates sustained toxicity in cancer cells and should be considered for use in patient care.
"Junk" DNA Critical for Heart Function
Loss of noncoding elements of genome, known as enhancers, results in abnormalities of heart functions.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos